120
Participants
Start Date
February 25, 2025
Primary Completion Date
December 31, 2025
Study Completion Date
March 31, 2026
Remimazolam
Remimazolam is an ultra-short acting benzodiazepine medication. Benzodiazepines are a class of drug that directly interact with gamma-aminobutyric acid (GABA) and modifiable chloride channels through polysynaptic pathway inhibition. The anxiolytic properties of benzodiazepines make them useful as sedatives.
Propofol
Standard of care usage of the intravenous anesthetic agent propofol to achieve adequate sedation conditions for the procedure.
RECRUITING
University of Alabama at Birmingham Hospital, Birmingham
University of Alabama at Birmingham
OTHER